Fighting Antibiotic Resistance with Point of Care Breath Analysis

通过护理点呼吸分析对抗抗生素耐药性

• 批准号: 48733
• 金额: $ 45.82万
• 依托单位: IMSPEX DIAGNOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=48733
• 关键词: Fighting; Antibiotic; Resistance; Point; Care

Due to the over prescription of antibiotics in cases where they do not help people get better, some bacteria have become resistant to them. To slow down this resistance, doctors need to prescribe less antibiotics in cases where they will not help. One way to do this is by developing a test to detect if a patient has a bacterial infection or not. This test should be quick, cheap and simple to undertake both at a GP surgery and in hospital and with no inconvenience a patient and preferably non-invasive.There is a need for a point-of-care (POC) diagnostics device to assist clinical decision making in the administration of antibiotics. Simply being able to identify if a patient is suffering from a bacterial, viral or fungal infection could produce a significant reduction in drug administration -- the key is to provide the clinician or GP the confidence NOT to prescribe a drugIMSPEX Diagnostics Ltd will further develop their Breathspec(r) device, which has already been successfully trialled on patients with respiratory tract infections. The developments are needed to make the Breathspec(r) device compliant with legislation for medical devices. As this is a complicated process, IMSPEX will have help from leading research scientists from Warwick University, specialist design engineers and the NHS. Creating a cost-effective, quick and easy-to-use test for deciding if patient have a bacterial or viral chest infection.IMSPEX Diagnostics Ltd will bring to market a diagnostic tool that can assist in antibiotic stewardship and rule out inappropriate antibiotic use. This will give both patients and doctors confidence in the decision to prescribe antibiotics or not. This concept is so innovative that there is currently no other company actively developing an AMR test that uses breath analysis. This means that there is an opportunity for IMSPEX Diagnostics to be first to market with such as test.

由于在抗生素不能帮助病人好转的情况下过度使用抗生素，一些细菌已经对它们产生了耐药性。为了减缓这种耐药性，医生需要在抗生素不起作用的情况下减少抗生素的处方。一种方法是开发一种检测病人是否有细菌感染的测试。无论是在全科医生诊所还是在医院，这项检测都应该是快速、廉价和简单的，不会给病人带来不便，最好是非侵入性的。有一个护理点（POC）诊断设备的需求，以协助临床决策在抗生素的管理。仅仅能够识别患者是否患有细菌，病毒或真菌感染就可以大大减少药物管理-关键是为临床医生或全科医生提供不开药的信心。imspex诊断有限公司将进一步开发他们的Breathspec(r)设备，该设备已经在呼吸道感染患者身上成功试验。为了使Breathspec(r)设备符合医疗设备的法规，需要进行开发。由于这是一个复杂的过程，IMSPEX将得到华威大学顶尖研究科学家、专业设计工程师和国民健康保险制度的帮助。创造一种具有成本效益，快速和易于使用的测试，以确定患者是否患有细菌性或病毒性胸部感染。IMSPEX诊断有限公司将向市场推出一种诊断工具，可以协助抗生素管理并排除不适当的抗生素使用。这将使患者和医生在决定是否开抗生素时都有信心。这个概念是如此创新，目前还没有其他公司积极开发使用呼吸分析的AMR测试。这意味着IMSPEX Diagnostics有机会率先将此类测试推向市场。